GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. faces a securities fraud class action lawsuit for failing to disclose material information about its acquisition performance. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, and disclosed a $31.2 million impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% on May 4, 2026, following the disappointing financial results and lowered guidance.